MOMCARE TABLET
November 10, 2017JESPER 50 TABLET
November 10, 2017
| LACTIMED TABLET |
Cabergoline Tablets |
| Composition : |
Each un-coated tablet contains 0.5 mg Cabergoline. |
| Indications : |
Inhibition/suppression of physiological lactation
Cabergoline is indicated for the inhibition of physiological lactation soon after delivery and for suppression of already established lactation:
1. After parturition, when the mother elects not to breast feed the infant or when breast feeding is contraindicated due to medical reasons related to the mother or the new-born.
2. After stillbirth or abortion.
Treatment of hyperprolactinaemic disorders
Cabergoline is indicated for the treatment of dysfunctions associated with hyperprolactinaemia, including amenorrhea, oligomenorrhoea, anovulation and galactorrhoea.
|
| Contraindications : |
Hypersensitivity to Cabergoline, any of the excipients or any ergot alkaloid; History of pulmonary, pericardial and retroperitoneal fibrotic disorders; patients with hepatic insufficiency and with toxaemia of pregnancy.
|
| Adverse Effects : |
Commonly reported adverse effects included ovarian enlargement, vasomotor flushes, abdominal-pelvic discomfort (distention, bloating), nausea and vomiting, breast discomfort, visual symptoms, headache and intermenstrual spotting or menorrhagia. |
| Dosage : |
Inhibition/suppression of physiological lactation
For inhibition of lactation Cabergoline should be administered during the first day post-partum. The recommended therapeutic dose is 1 mg (two 0.5 mg tablets) given as a single dose.
For suppression of established lactation the recommended therapeutic dosage regimen is 0.25 mg (one-half 0.5 mg tablet) every 12 hours for two days (1 mg total dose).
Treatment of hyperprolactinaemic disorders
The recommended initial dosage of Cabergoline is 0.5 mg per week given in one or two (one-half of one 0.5 mg tablet) doses (e.g. on Monday and Thursday) per week. The weekly dose should be increased gradually, preferably by adding 0.5 mg per week at monthly intervals until an optimal therapeutic response is achieved. The therapeutic dosage is usually 1 mg per week and ranges from 0.25 mg to 2 mg per week. Doses of Cabergoline up to 4.5 mg per week have been used in hyperprolactinaemic patients
|
